Compare IBCP & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBCP | IOVA |
|---|---|---|
| Founded | 1864 | 2007 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 674.7M | 1.6B |
| IPO Year | 2010 | 2008 |
| Metric | IBCP | IOVA |
|---|---|---|
| Price | $32.55 | $3.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $36.67 | $9.11 |
| AVG Volume (30 Days) | 144.4K | ★ 18.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | 3.48 | ★ 14.84 |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $32,075,000.00 | N/A |
| Revenue This Year | N/A | $51.55 |
| Revenue Next Year | $5.46 | $37.55 |
| P/E Ratio | $10.05 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $26.75 | $1.64 |
| 52 Week High | $37.39 | $5.63 |
| Indicator | IBCP | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 49.05 |
| Support Level | $30.09 | $2.02 |
| Resistance Level | $33.47 | $4.34 |
| Average True Range (ATR) | 0.98 | 0.41 |
| MACD | -0.09 | -0.14 |
| Stochastic Oscillator | 32.91 | 12.95 |
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.